Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1

Cell Reports

Volumn 16, Issue 6, 2016, Pages 1604-1613

  Locke, Matthew ^a,c   Ghazaly, Essam ^a   Freitas, Marta O ^a   Mitsinga, Mikaella ^a   Lattanzio, Laura ^b   Lo Nigro, Cristiana ^b   Nagano, Ai ^a   Wang, Jun ^a   Chelala, Claude ^a   Szlosarek, Peter ^a   Martin, Sarah A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHASE 1; PEGARGIMINASE; POLYAMINE; UNCLASSIFIED DRUG; HYDROLASE; MACROGOL DERIVATIVE;

ACETYLATION; ARTICLE; CANCER CELL; CHEMICAL INTERACTION; CONTROLLED STUDY; DEMETHYLATION; HUMAN; HUMAN CELL; LETHALITY; MESOTHELIOMA; METABOLITE; POLYAMINE METABOLISM; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; DEFICIENCY; DNA METHYLATION; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ARGININE; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; DNA METHYLATION; HUMANS; HYDROLASES; LUNG NEOPLASMS; MESOTHELIOMA; POLYAMINES; POLYETHYLENE GLYCOLS; PROMOTER REGIONS, GENETIC;

EID: 84989931404     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.06.097     Document Type: Article

References (44)

1. Allen, M.D., Luong, P., Hudson, C., Leyton, J., Delage, B., Ghazaly, E., Cutts, R., Yuan, M., Syed, N., Lo Nigro, C., et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res. 74 (2014), 896–907.
2. Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M., Melino, G., Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39 (2014), 191–198.
3. Bachrach, U., Wang, Y.C., Tabib, A., Polyamines: new cues in cellular signal transduction. News Physiol. Sci. 16 (2001), 106–109.
4. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57 (1995), 289–300.
5. Brabender, J., Lord, R.V., Danenberg, K.D., Metzger, R., Schneider, P.M., Uetake, H., Kawakami, K., Park, J.M., Salonga, D., Peters, J.H., et al. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J. Gastrointest. Surg. 5 (2001), 174–181, discussion 182.
6. Cheong, J.H., Park, E.S., Liang, J., Dennison, J.B., Tsavachidou, D., Nguyen-Charles, C., Wa Cheng, K., Hall, H., Zhang, D., Lu, Y., et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10 (2011), 2350–2362.
7. Cutts, R.J., Dayem Ullah, A.Z., Sangaralingam, A., Gadaleta, E., Lemoine, N.R., Chelala, C., O-miner: an integrative platform for automated analysis and mining of -omics data. Nucleic Acids Res., 40, 2012 W560-8.
8. Delage, B., Fennell, D.A., Nicholson, L., McNeish, I., Lemoine, N.R., Crook, T., Szlosarek, P.W., Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 126 (2010), 2762–2772.
9. Delage, B., Luong, P., Maharaj, L., O'Riain, C., Syed, N., Crook, T., Hatzimichael, E., Papoudou-Bai, A., Mitchell, T.J., Whittaker, S.J., et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis., 3, 2012, e342.
10. Feun, L., You, M., Wu, C.J., Kuo, M.T., Wangpaichitr, M., Spector, S., Savaraj, N., Arginine deprivation as a targeted therapy for cancer. Curr. Pharm. Des. 14 (2008), 1049–1057.
11. Frezza, C., Zheng, L., Folger, O., Rajagopalan, K.N., MacKenzie, E.D., Jerby, L., Micaroni, M., Chaneton, B., Adam, J., Hedley, A., et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477 (2011), 225–228.
12. Frezza, C., Zheng, L., Tennant, D.A., Papkovsky, D.B., Hedley, B.A., Kalna, G., Watson, D.G., Gottlieb, E., Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS ONE, 6, 2011, e24411.
13. Gerner, E.W., Meyskens, F.L. Jr., Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4 (2004), 781–792.
14. Huang, H.Y., Wu, W.R., Wang, Y.H., Wang, J.W., Fang, F.M., Tsai, J.W., Li, S.H., Hung, H.C., Yu, S.C., Lan, J., et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin. Cancer Res. 19 (2013), 2861–2872.
15. Jobgen, W.S., Fried, S.K., Fu, W.J., Meininger, C.J., Wu, G., Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J. Nutr. Biochem. 17 (2006), 571–588.
16. King, A., Selak, M.A., Gottlieb, E., Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25 (2006), 4675–4682.
17. Kramer, D.L., Diegelman, P., Jell, J., Vujcic, S., Merali, S., Porter, C.W., Polyamine acetylation modulates polyamine metabolic flux, a prelude to broader metabolic consequences. J. Biol. Chem. 283 (2008), 4241–4251.
18. Lan, J., Tai, H.C., Lee, S.W., Chen, T.J., Huang, H.Y., Li, C.F., Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol. 35 (2014), 161–169.
19. Le, A., Cooper, C.R., Gouw, A.M., Dinavahi, R., Maitra, A., Deck, L.M., Royer, R.E., Vander Jagt, D.L., Semenza, G.L., Dang, C.V., Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA 107 (2010), 2037–2042.
20. Leuzzi, V., Alessandrì, M.G., Casarano, M., Battini, R., Cioni, G., Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts. Anal. Biochem. 375 (2008), 153–155.
21. Lind, D.S., Arginine and cancer. J. Nutr. 134 (2004), 2837S–2841S discussion 2853S.
22. Liu, R., Li, Q., Ma, R., Lin, X., Xu, H., Bi, K., Determination of polyamine metabolome in plasma and urine by ultrahigh performance liquid chromatography-tandem mass spectrometry method: application to identify potential markers for human hepatic cancer. Anal. Chim. Acta 791 (2013), 36–45.
23. Long, Y., Tsai, W.B., Wangpaichitr, M., Tsukamoto, T., Savaraj, N., Feun, L.G., Kuo, M.T., Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol. Cancer Ther. 12 (2013), 2581–2590.
24. Magnes, C., Fauland, A., Gander, E., Narath, S., Ratzer, M., Eisenberg, T., Madeo, F., Pieber, T., Sinner, F., Polyamines in biological samples: rapid and robust quantification by solid-phase extraction online-coupled to liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1331 (2014), 44–51.
25. Mandal, S., Mandal, A., Johansson, H.E., Orjalo, A.V., Park, M.H., Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc. Natl. Acad. Sci. USA 110 (2013), 2169–2174.
26. McAlpine, J.A., Lu, H.T., Wu, K.C., Knowles, S.K., Thomson, J.A., Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer, 14, 2014, 621.
27. McGarrity, T.J., Peiffer, L.P., Bartholomew, M.J., Pegg, A.E., Colonic polyamine content and ornithine decarboxylase activity as markers for adenomas. Cancer 66 (1990), 1539–1543.
28. Muller, F.L., Colla, S., Aquilanti, E., Manzo, V.E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488 (2012), 337–342.
29. Ott, P.A., Carvajal, R.D., Pandit-Taskar, N., Jungbluth, A.A., Hoffman, E.W., Wu, B.W., Bomalaski, J.S., Venhaus, R., Pan, L., Old, L.J., et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest. New Drugs 31 (2013), 425–434.
30. Pandher, R., Ducruix, C., Eccles, S.A., Raynaud, F.I., Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (2009), 1352–1358.
31. Rabinovich, S., Adler, L., Yizhak, K., Sarver, A., Silberman, A., Agron, S., Stettner, N., Sun, Q., Brandis, A., Helbling, D., et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature 527 (2015), 379–383.
32. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
33. Shin, S., Fung, S.M., Mohan, S., Fung, H.L., Simultaneous bioanalysis of L-arginine, L-citrulline, and dimethylarginines by LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2011), 467–474.
34. Synakiewicz, A., Stachowicz-Stencel, T., Adamkiewicz-Drozynska, E., The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Expert Opin. Investig. Drugs 23 (2014), 1517–1529.
35. Szlosarek, P.W., Klabatsa, A., Pallaska, A., Sheaff, M., Smith, P., Crook, T., Grimshaw, M.J., Steele, J.P., Rudd, R.M., Balkwill, F.R., Fennell, D.A., In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin. Cancer Res. 12 (2006), 7126–7131.
36. Szlosarek, P.W., Luong, P., Phillips, M.M., Baccarini, M., Stephen, E., Szyszko, T., Sheaff, M.T., Avril, N., Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J. Clin. Oncol. 31 (2013), e111–e113.
37. Tabib, A., Bachrach, U., Role of polyamines in mediating malignant transformation and oncogene expression. Int. J. Biochem. Cell Biol. 31 (1999), 1289–1295.
38. Tomlinson, I.P., Alam, N.A., Rowan, A.J., Barclay, E., Jaeger, E.E., Kelsell, D., Leigh, I., Gorman, P., Lamlum, H., Rahman, S., et al., Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30 (2002), 406–410.
39. Tsai, W.B., Aiba, I., Lee, S.Y., Feun, L., Savaraj, N., Kuo, M.T., Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol. Cancer Ther. 8 (2009), 3223–3233.
40. Tsun, Z.Y., Possemato, R., Amino acid management in cancer. Semin. Cell Dev. Biol. 43 (2015), 22–32.
41. Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003), 2636–2644.
42. Wang, W., Liu, L.Q., Higuchi, C.M., Mucosal polyamine measurements and colorectal cancer risk. J. Cell. Biochem. 63 (1996), 252–257.
43. Wise, D.R., Thompson, C.B., Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35 (2010), 427–433.
44. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360 (2009), 765–773.